Evidence map›Paper›PMID 36304424›Full record

ArticleJournal of pharmacy and pharmacology research2022

Age-Dependent Heterogeneity of Lymph Node Metastases and Survival Identified by Analysis of a National Breast Cancer Registry.

Michael Behring, Prachi Bajpai, Farrukh Afaq, Amr Elkholy, Hyung-Gyoon Kim, Sameer Al Diffalha, Sadeep Shrestha, Upender Manne

Open access · diamondAbstract read
In one paragraph

Article in Journal of pharmacy and pharmacology research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Michael BehringDepartment of Pathology.
Prachi BajpaiDepartment of Pathology.
Farrukh AfaqDepartment of Pathology.
Amr ElkholyDepartment of Pathology.
Hyung-Gyoon KimDepartment of Pathology.
Sameer Al DiffalhaDepartment of Pathology.
Sadeep ShresthaO'Neal Comprehensive Cancer Center.
Upender ManneDepartment of Pathology.
O'Neal Comprehensive Cancer CenterAthens State University · US

Funding

TRAINING AND CAREER DEVELOPMENTU54CA118948 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Timiya S Nolan · 2005 to 2026
$26.6M
Cancer Prevention & Control Training ProgramR25CA047888 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI DEMARK-WAHNEFRIED, WENDY, MENESES, KAREN M · 1988 to 2016
$11.2M
UAB Cancer Prevention and Control Training Program (T32)T32CA047888 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Ritu Aneja, Ellen Mary Lavoie Smith · 2018 to 2026
$3.2M
NCI NIH HHS R25 CA047888NCI NIH HHS T32 CA047888NCI NIH HHS U54 CA118948
6 · The paper itself

Abstract

Background: For several cancers, including those of the breast, young age at diagnosis is associated with an adverse prognosis. Although this effect is often attributed to heritable mutations such as BRCA1/2, the relationship between pathologic features, young age of onset, and prognosis for breast cancer remains unclear. In the present study, we highlight links between age of onset and lymph node metastasis (NM) in US women with breast cancer. Methods: Case listings from Surveillance, Epidemiology, and End Result (SEER) 18 registry data for women with breast cancer, which include information on race, were used. NM and its associated outcomes were evaluated for a subset of women with receptor subtype information and then compared against a larger, pre-subtype validation set of data from the same registry. Age of diagnosis was a 5-category variable; under 40 years, 40-49 years, 50-59 years, 60-69 years and 70+ years. Univariate and adjusted multivariate survival models were applied to both sets of data. Results: As determined with adjusted logistic regression models, women under 40 years old at diagnosis had 1.55 times the odds of NM as women 60-69 years of age. The odds of NM for (HR = hormone receptor) HR+/HER2+, HR-/HER2+, and triple-negative breast cancer subtypes were significantly lower than those for HR+/HER2-. In subtype-stratified adjusted models, age of diagnosis had a consistent trend of decreasing odds of NM by age category, most noticeable for HR+ subtypes of luminal A and B. Univariate 5-year survival by age was worst for women under 40 years, with NM attributable for 49% of the hazard of death from cancer in adjusted multivariate models. Conclusions: Lymph node metastasis is age-dependent, yet not all molecular subtypes are clearly affected by this relationship. For <40-yr-old women, NM is a major cause for shorter survival. When stratified by subtype, the strongest associations were in HR+ groups, suggesting a possible hormonal connection between young age of breast cancer onset and NM.

Indexed as

Breast cancerearly age of diagnosisNodal metastasisSEER cancer registry

Identifiers

PMID36304424
PMCPMC9601600
OpenAlexW4296502916

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.